SPDR S&P BIOTECH ETF (XBI)
| Assets | $4.79B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 64.95M |
| Dividend (ttm) | $0.14 |
| Dividend Yield | 0.18% |
| Ex-Dividend Date | Mar 24, 2025 |
| Payout Ratio | n/a |
| 1-Year Return | -13.17% |
| Volume | 8,638,175 |
| Open | 76.49 |
| Previous Close | 76.54 |
| Day's Range | 75.59 - 77.56 |
| 52-Week Low | 66.66 |
| 52-Week High | 105.47 |
| Beta | 1.00 |
| Holdings | 130 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe SPDR S&P BIOTECH ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
26.04% of assets| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 2.82% |
| Vertex Pharmaceuticals Incorporated | VRTX | 2.74% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.71% |
| Insmed Incorporated | INSM | 2.63% |
| Exact Sciences Corporation | EXAS | 2.62% |
| Amgen Inc. | AMGN | 2.58% |
| Gilead Sciences, Inc. | GILD | 2.56% |
| United Therapeutics Corporation | UTHR | 2.54% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 2.44% |
| Incyte Corporation | INCY | 2.40% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 24, 2025 | $0.00525 | Mar 26, 2025 |
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
| Sep 23, 2024 | $0.01523 | Sep 25, 2024 |
| Jun 24, 2024 | $0.11478 | Jun 26, 2024 |
| Dec 18, 2023 | $0.01388 | Dec 21, 2023 |
| Jun 20, 2023 | $0.00262 | Jun 23, 2023 |
News
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Single stock picking is the only way to make money in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Invest In A New Biotech Bull Market With XBI And IBB
Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides mor...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months
XBI: Diverse Holding Amid Strong Catalysts, Buy
SPDR® S&P Biotech ETF is a strong investment due to rising demand for biotech solutions addressing chronic diseases and its diverse, equal-weighted portfolio. XBI's equal-weighting strategy reduces co...
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Healthcare Stocks: 2025 Outlook
I forecast healthcare stocks, especially biopharmaceuticals, to outperform the general averages due to four key investment themes. US healthcare expenditures are expected to grow at an annualized rate...
Trade Tracker: Joe Terranova buys the XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss why he's buying the Biotech ETF.
Final Trade: LNG, XLP, X, XBI
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders.
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thu...
Finding Winners In Biotech, Probably The Riskiest Sector
Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year c...
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leadin...
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
XBI: Biotech ETF Is A Must Have
SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the Russel...
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu...